ClinChoice Medical Development is pleased to announce the acquisition of CROMSOURCE Srl, an ISO-certified full-service contract research organization headquartered in Verona , Italy and its US headquarters in Cary, North Carolina . CROMSOURCE has offices in the United States and in seven countries in Western and Eastern Europe, as well as field representatives in various locations in Europe and the United States .

Founded in 1997, CROMSOURCE has a proven track record of supporting global pharmaceutical, biotechnology and medical device clients with exceptional clinical research and recruitment capabilities. The acquisition will strengthen ClinChoice's global network and expand its full-service capabilities.

ClinChoice's commitment to superior quality and timely delivery of its services has resulted in a strong track record of successfully conducting clinical trials and functions including biometrics, regulatory, security, medical and clinical operations. ClinChoice offers these services in the pharmaceutical, medical device, vaccine, cosmetic and consumer health sectors, utilizing both project-based and FSP models. As a global CRO, ClinChoice provides full development cycle solutions for pharmaceutical, biotechnology, medical device and consumer products companies worldwide. The company's clientele ranges from the largest multinationals to start-ups and emerging companies. ClinChoice has more than 1.

“We look forward to working with CROMSOURCE and expanding our footprint in Europe and the US to better serve the needs of our global customers, accelerate product development and support lifecycle management. Strategically, the acquisition of CROMSOURCE provides us with a highly experienced team of operational and technical experts in Europe and North America, expanding our existing capabilities in clinical development and staffing solutions," said Ling Zhen, Chairman and Global CEO of ClinChoice .

“The acquisition of CROMSOURCE brings significant improvements to our talent pool. It expands our operational capabilities with additional delivery centers to complement our current network in Europe and the US . This merger also expands our data science technology offerings in many areas, including decentralized clinical trials and risk-based surveillance," said John Balian , co-founder and CEO of ClinChoice , Inc, who leads the company's operations in the US , Europe and Southeast Asia.

The founder and CEO of CROMSOURCE , Dr. medical Oriana Zerbini , remarked, “We are very excited to bring together the highly experienced and talented team at CROMSOURCE with that at ClinChoice. The two companies offer such clear synergies that it was a very easy decision to join Ling Zhen , John Balian and the rest of ClinChoice's impressive team. We look forward to becoming the CRO partner of choice for customers worldwide."

CROMSOURCE was advised by Fairmount Partners and ClinChoice was represented by Crosstree Capital.

About ClinChoice
ClinChoice is a global clinical contract research organization (CRO) providing high quality services to biopharmaceutical, vaccine, medical device and consumer products companies. These services include clinical operations, project management, biostatistics, data management, regulatory and medical affairs, pharmacovigilance, cosmetovigilance, toxicology, as well as medical writing and other product development services. ClinChoice has delivery centers in the US , Europe, Canada, China , India, Japan and the Philippines with more than 4,000 dedicated professionals.

About CROMSOURCE
CROMSOURCE is an ISO-certified, international, full-service CRO specializing in clinical operations and development, as well as flexible outsourcing solutions delivered by enduring teams of experienced professionals. CROMSOURCE has branches in all regions of Europe and North America and carries out projects worldwide.

 

Source:prnewswire.com

Report Abuse